This document discusses malignant neoplasms of the endometrium, ovary, fallopian tube and peritoneum. It provides details on endometrial cancer, including risk factors, symptoms, diagnostic methods, histologic classification, staging, patterns of spread, evaluation and surgery. Key points include that endometrial cancer most commonly affects postmenopausal women, diagnostic methods include endometrial biopsy and hysteroscopy, the most common histologic type is endometrioid adenocarcinoma, and surgery is the primary treatment but exceptions may be made for high surgical risk patients.
Dr. Niranjan Chavan discusses oncofertility, an interdisciplinary field that explores fertility options for cancer patients. He outlines various fertility preservation options available for patients with ovarian cancer, cervical cancer, and endometrial cancer. These include conservative surgeries, ovarian tissue cryopreservation, oocyte or embryo cryopreservation, and hormonal therapies. Dr. Chavan emphasizes the importance of discussing fertility preservation with cancer patients before treatment starts and providing referrals to fertility specialists.
Fertility Preservation In Cancer Pt Finguest7f0a3a
The document discusses several methods for preserving fertility in cancer patients, including:
1) Embryo freezing and ovarian tissue banking which allow patients to preserve eggs or embryos before cancer treatment.
2) The use of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy to protect ovarian follicles, based on a preliminary study showing it effectively preserved fertility.
3) Cryopreservation of immature or mature eggs, though success rates for mature egg freezing are still low due to challenges with ice crystal formation during slow freezing methods. New vitrification techniques may improve survival rates.
This document discusses sonographic criteria for uterine curettage when endometrial neoplasia is suspected. Eight premenopausal and perimenopausal women underwent transvaginal ultrasounds and uterine curettage due to abnormal bleeding or discharge. Histopathology found hyperplasia in polycystic ovary syndrome patients and cancer in a patient on tamoxifen therapy. Key ultrasound findings associated with hyperplasia or cancer included thick irregular endometrium, ill-defined endometrial-myometrial junction, intrauterine fluid collections, adnexal masses, and cystic endometrial areas. The document concludes that endometrial stripe abnormalities on ultrasound, in addition to thickness, are important
Cancer survivors are increasing because of advances in early detection and treatment options. Fertility preservation in cancer patients gives hope to have a family later in life. Spread the awareness about fertility preservation to fulfill the dream of parenthood..!!!
This document provides guidelines for the management of endometrial cancer from several European medical societies. It covers epidemiology, risk assessment, surgery, lymph node staging, adjuvant therapy, and management of early, advanced, and recurrent disease. Key points include recommending total hysterectomy and bilateral salpingo-oophorectomy for staging without vaginal cuff resection for early-stage disease. It also supports consideration of sentinel lymph node biopsy for staging in select cases and ovarian preservation in certain low-risk premenopausal patients. Molecular testing is encouraged to further stratify prognosis, especially in high-grade tumors.
This document discusses fertility preservation options for cancer patients. It begins by noting that advances in cancer treatment have led to improved survival rates but also increased risks of infertility. It then discusses the field of oncofertility, which aims to provide fertility preservation options for young cancer patients. The document reviews fertility preservation guidelines and options for both female and male patients, including embryo/oocyte cryopreservation, ovarian tissue cryopreservation, and sperm cryopreservation. It stresses the importance of discussing fertility preservation with patients before starting cancer treatment.
Dr. Niranjan Chavan discusses oncofertility, an interdisciplinary field that explores fertility options for cancer patients. He outlines various fertility preservation options available for patients with ovarian cancer, cervical cancer, and endometrial cancer. These include conservative surgeries, ovarian tissue cryopreservation, oocyte or embryo cryopreservation, and hormonal therapies. Dr. Chavan emphasizes the importance of discussing fertility preservation with cancer patients before treatment starts and providing referrals to fertility specialists.
Fertility Preservation In Cancer Pt Finguest7f0a3a
The document discusses several methods for preserving fertility in cancer patients, including:
1) Embryo freezing and ovarian tissue banking which allow patients to preserve eggs or embryos before cancer treatment.
2) The use of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy to protect ovarian follicles, based on a preliminary study showing it effectively preserved fertility.
3) Cryopreservation of immature or mature eggs, though success rates for mature egg freezing are still low due to challenges with ice crystal formation during slow freezing methods. New vitrification techniques may improve survival rates.
This document discusses sonographic criteria for uterine curettage when endometrial neoplasia is suspected. Eight premenopausal and perimenopausal women underwent transvaginal ultrasounds and uterine curettage due to abnormal bleeding or discharge. Histopathology found hyperplasia in polycystic ovary syndrome patients and cancer in a patient on tamoxifen therapy. Key ultrasound findings associated with hyperplasia or cancer included thick irregular endometrium, ill-defined endometrial-myometrial junction, intrauterine fluid collections, adnexal masses, and cystic endometrial areas. The document concludes that endometrial stripe abnormalities on ultrasound, in addition to thickness, are important
Cancer survivors are increasing because of advances in early detection and treatment options. Fertility preservation in cancer patients gives hope to have a family later in life. Spread the awareness about fertility preservation to fulfill the dream of parenthood..!!!
This document provides guidelines for the management of endometrial cancer from several European medical societies. It covers epidemiology, risk assessment, surgery, lymph node staging, adjuvant therapy, and management of early, advanced, and recurrent disease. Key points include recommending total hysterectomy and bilateral salpingo-oophorectomy for staging without vaginal cuff resection for early-stage disease. It also supports consideration of sentinel lymph node biopsy for staging in select cases and ovarian preservation in certain low-risk premenopausal patients. Molecular testing is encouraged to further stratify prognosis, especially in high-grade tumors.
This document discusses fertility preservation options for cancer patients. It begins by noting that advances in cancer treatment have led to improved survival rates but also increased risks of infertility. It then discusses the field of oncofertility, which aims to provide fertility preservation options for young cancer patients. The document reviews fertility preservation guidelines and options for both female and male patients, including embryo/oocyte cryopreservation, ovarian tissue cryopreservation, and sperm cryopreservation. It stresses the importance of discussing fertility preservation with patients before starting cancer treatment.
Gynaecological oncology for the mrcog and beyond, 2e 2nermine amin
This book provides a concise yet comprehensive overview of gynaecological oncology for those preparing for the MRCOG exam or seeking to further their knowledge. It has been updated from the first edition to reflect recent developments in multidisciplinary care and advanced training. The chapters cover the epidemiology, pathology, diagnosis and management of the main gynaecological cancers according to the latest evidence and standards of care. Additional chapters address related topics such as preinvasive disease, imaging, surgery, radiotherapy, chemotherapy, palliative care and complications. The book serves as a valuable resource for all clinicians involved in the care of women with gynaecological cancer.
This document discusses ovarian cancer prevention. It notes that ovarian cancer risk increases with age and factors like family history and endometriosis. Screening is not recommended for average risk women as trials found it did not reduce mortality and caused harm. Two main types of ovarian cancer have different origins - type II tumors often originate in the fallopian tubes. Prevention strategies discussed include risk-reducing salpingo-oophorectomies, oral contraceptives, metformin, NSAIDs, vitamins, and physical activity, which may reduce inflammation and hormones linked to cancer.
This study investigated the associations between premenopausal hysterectomy and oophorectomy with breast cancer risk among black and white women in North Carolina between 1993 and 2001. The study found:
1) Both bilateral oophorectomy and hysterectomy without oophorectomy were associated with lower odds of breast cancer compared to no premenopausal surgery.
2) The estimates did not vary by race and were similar for hormone receptor-positive and hormone receptor-negative cancers.
3) Use of estrogen-only menopausal hormone therapy did not attenuate the associations between premenopausal surgery and lower breast cancer risk.
Uterine Cancer Recurrence: All You Need To Knowbkling
t's not uncommon for uterine cancer survivors to worry about recurrence.
Whether you've had a recurrence or want to become more informed, join Dr. Susan C. Modesitt, Director of Gynecologic Oncology at UVA Cancer Center, to learn more information about uterine cancer recurrence as well as available treatment options.
Fertility preservation options are important for cancer patients of reproductive age undergoing treatment. For women, established options include embryo freezing for married patients and oocyte freezing for single patients, both of which require delaying cancer treatment. Ovarian tissue freezing can be done at any age or relationship status and does not delay treatment, but reimplantation success is currently low. For pre-pubertal patients, ovarian tissue or testicular tissue freezing are the only available options. Future methods may allow in vitro gamete maturation or stem cell derived gametes. Multidisciplinary care and individualized counseling are key to help patients preserve their fertility whenever possible before cancer treatment.
Endometrial cancer starts when cells in the inner lining of the uterus grow abnormally and can spread. Some key risk factors include excess estrogen exposure without progesterone opposition, obesity, late menopause, and family history. Common symptoms are abnormal vaginal bleeding or discharge. Diagnosis involves endometrial biopsy and other imaging tests. Treatment options include surgery to remove the uterus and surrounding tissue, radiation therapy, chemotherapy, hormone therapy, and targeted therapies. The cancer is staged based on how much it has spread in the body.
Fertility preservation in Cancer patientsArunSharma10
The need for fertility preservation
Chemotherapeutic drugs according to gonadotoxicity level
Fertility preservation: subject of continuous review by experts
Non-oncological conditions requiring fertility preservation
Delayed childbearing
AVAILABLE PROCEDURES FOR FP
Embryo and oocyte cryopreservation
fertililty sparing surgeries in gynecological cancersSreelasya Kakarla
- Fertility preservation is important for cancer patients of childbearing age to maintain their quality of life. Advances in cancer treatment like chemotherapy and radiation can impact fertility.
- For early stage cervical cancers like stage 1A1, 1A2, and 1B1, fertility sparing surgeries like conization or radical trachelectomy combined with lymph node dissection may be options to preserve fertility while treating the cancer.
- For early stage ovarian and endometrial cancers, fertility sparing surgeries like cystectomy or tumor resection with lymph node sampling can be considered to treat the cancer and spare fertility in select cases.
Menopause for the mrcog and beyond, second editionnermine amin
This document discusses definitions related to menopause and controversies surrounding hormone replacement therapy (HRT). It defines key terms like menopause, perimenopause, and postmenopause. It also outlines the stages of reproductive aging. Two large studies, the Women's Health Initiative (WHI) and Million Women Study, found risks of HRT that led to controversies. The WHI was a randomized clinical trial of over 68,000 women aged 50-79 investigating HRT and other interventions. It found HRT increased risks of breast cancer, stroke, and heart disease and was stopped early.
Deborah Collyar, President, Patient Advocates In Research, discusses what new research is telling us about DCIS, both here and abroad. What is low risk DCIS? Is it okay to monitor your DCIS? Is Endocrine Therapy absolutely necessary? What does the future look like? Deborah addresses this and so much more.
This research article examines the incidence and consequences of unexpected malignancy or lesions following power morcellation during minimally invasive surgery for presumed uterine fibroids. The study analyzed 3013 laparoscopic myomectomies performed over 10 years. It found an unexpected diagnosis rate of 0.23%, including sarcomas in 0.10% of cases. One of the four patients who underwent staging surgery following diagnosis was found to have peritoneal dissemination and died from the disease. The risks of disseminating unexpected malignancy and poor long term outcomes are concerning. The article discusses the debate around continuing versus restricting power morcellation and the need for improved pre-operative diagnostic tools and patient counseling on alternative treatment options and risks.
Diagnosis of endometriosis in the 21 st centuryArunSharma10
Diagnosis of endometriosis is a challenge
Unmet needs in diagnosis of endometriosis
Non-invasive diagnosis of endometriosis
Urinary biomarkers
Peripheral biomarkers
Genetic predisposition in endometriosis
Genetic tests in endometriosis
Tissue biomarkers
miRNAs in the diagnosis of endometriosis
Endometriosis diagnosis
Introduction: Ovarian reserve is defi ned as the existent quantitative and qualitative follicular supply found in the ovaries which may turn into mature follicles and assigns a woman’s reproductive potential. The commonly appointed tests of ovarian reserve can be divided into static markers (FSH, estradiol, inhibin-B and [AMH] Anti-Mullerian Hormone), dynamic markers (clomiphene citrate, gonadotrophins and Gonadotrophin Releasing Hormone [GnRh] analogue stimulation tests) and ultrasonographic markers (Antral Follicle Count [AFC],
ovarian volume and ovarian blood fl ow). Leiomyomas are the most common genital tract tumors of benign nature and the most frequent benign uterine disorder in women of reproductive period.
This document provides information about breast cancer trends and facts. It discusses:
- Breast cancer is the most common cancer in women and the second leading cause of cancer death in women. Incidence rates have been rising but mortality rates have been declining since 1989 due to earlier detection and improved treatments.
- Risk factors include age, family history, dense breasts, obesity, hormone therapy use, alcohol consumption and lack of physical activity. Molecular subtypes have different survival rates and prevalence among racial groups.
- Screening guidelines and risk assessment tools can help determine screening recommendations for average and high-risk women. Lifestyle changes like diet, exercise and weight management may lower risk. Targeted therapies have improved survival for HER2
This review article discusses when hysterectomy should replace myomectomy for treating benign uterine conditions like fibroids. It summarizes various treatment options for fibroids including myomectomy, hysterectomy, uterine artery embolization, magnetic resonance-guided focused ultrasound, and hormonal therapies. The costs of fibroids and different surgical approaches like hysteroscopic, laparoscopic, and robotic myomectomy are also considered. Key factors in deciding between myomectomy and hysterectomy include the patient's desire to preserve fertility, the size and location of fibroids, risk of recurrence, and potential for complications.
This document discusses fertility preservation options for adolescents and young adults undergoing cancer treatment. It provides an overview of the risks cancer treatments pose to fertility for both males and females. For males, sperm banking and testicular tissue freezing are discussed as options. For females, embryo banking, oocyte cryopreservation, and ovarian tissue freezing are covered, though many methods are still considered experimental. The challenges of discussing fertility with young patients and barriers to accessing fertility preservation are also summarized.
Fertility preservation in cancer patientsRohit Kabre
This document discusses fertility preservation options for cancer patients undergoing treatment. It outlines how chemotherapy and radiation can damage the ovaries and testes, potentially causing infertility. It reviews fertility preservation methods like embryo, oocyte, and sperm cryopreservation, which are established options. Experimental options discussed include ovarian tissue and testicular tissue cryopreservation. The document also summarizes ASCO guidelines recommending discussing fertility preservation with all eligible patients and referring them to specialists.
This document summarizes several breast cancer risk assessment models. It discusses two main types of risk assessment: the chances of developing breast cancer over time, and the chances of carrying a mutation in a high-risk gene like BRCA1/2. Several models are described that assess these risks, including the Gail model, Claus model, BRCAPRO, and Cuzick-Tyrer models. Each model incorporates different sets of risk factors and has varying levels of validation and ability to predict cancer risk. The document advocates that improved models integrating more genetic and lifestyle risk factors could achieve more accurate individualized risk prediction.
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
- Metastatic breast cancer poses significant challenges as it is incurable and can recur even after early-stage treatment, with over 500,000 deaths worldwide annually. Living with metastatic disease differs profoundly from early-stage experiences.
- Two surveys of over 1,000 metastatic breast cancer patients across countries found high levels of fear, confusion and depression upon diagnosis. While most received family support, many felt stigma and isolation. Information seeking helped patients cope.
- More research funding and clinical trials inclusive of quality of life are needed. Counting metastatic cases is important to assess needs and allocate resources for supportive care and treatments that meaningfully extend survival and quality of life for these patients. Guidelines can help patients navigate a still deadly disease.
- Endometrial hyperplasia is an abnormal proliferation of the endometrium that can develop due to unopposed estrogen stimulation. It is classified based on complexity of the glands and presence of atypia.
- Risk factors include obesity, estrogen therapy without progesterone, tamoxifen use, and hereditary conditions. Symptoms include abnormal vaginal bleeding. Diagnosis involves ultrasound and endometrial biopsy.
- Treatment options include progestin therapy, which can cause regression in many cases. Hysterectomy is recommended for atypical or complex hyperplasia that is resistant to medical management due to increased risk of progression to cancer. Close monitoring is required after treatment.
Gynaecological oncology for the mrcog and beyond, 2e 2nermine amin
This book provides a concise yet comprehensive overview of gynaecological oncology for those preparing for the MRCOG exam or seeking to further their knowledge. It has been updated from the first edition to reflect recent developments in multidisciplinary care and advanced training. The chapters cover the epidemiology, pathology, diagnosis and management of the main gynaecological cancers according to the latest evidence and standards of care. Additional chapters address related topics such as preinvasive disease, imaging, surgery, radiotherapy, chemotherapy, palliative care and complications. The book serves as a valuable resource for all clinicians involved in the care of women with gynaecological cancer.
This document discusses ovarian cancer prevention. It notes that ovarian cancer risk increases with age and factors like family history and endometriosis. Screening is not recommended for average risk women as trials found it did not reduce mortality and caused harm. Two main types of ovarian cancer have different origins - type II tumors often originate in the fallopian tubes. Prevention strategies discussed include risk-reducing salpingo-oophorectomies, oral contraceptives, metformin, NSAIDs, vitamins, and physical activity, which may reduce inflammation and hormones linked to cancer.
This study investigated the associations between premenopausal hysterectomy and oophorectomy with breast cancer risk among black and white women in North Carolina between 1993 and 2001. The study found:
1) Both bilateral oophorectomy and hysterectomy without oophorectomy were associated with lower odds of breast cancer compared to no premenopausal surgery.
2) The estimates did not vary by race and were similar for hormone receptor-positive and hormone receptor-negative cancers.
3) Use of estrogen-only menopausal hormone therapy did not attenuate the associations between premenopausal surgery and lower breast cancer risk.
Uterine Cancer Recurrence: All You Need To Knowbkling
t's not uncommon for uterine cancer survivors to worry about recurrence.
Whether you've had a recurrence or want to become more informed, join Dr. Susan C. Modesitt, Director of Gynecologic Oncology at UVA Cancer Center, to learn more information about uterine cancer recurrence as well as available treatment options.
Fertility preservation options are important for cancer patients of reproductive age undergoing treatment. For women, established options include embryo freezing for married patients and oocyte freezing for single patients, both of which require delaying cancer treatment. Ovarian tissue freezing can be done at any age or relationship status and does not delay treatment, but reimplantation success is currently low. For pre-pubertal patients, ovarian tissue or testicular tissue freezing are the only available options. Future methods may allow in vitro gamete maturation or stem cell derived gametes. Multidisciplinary care and individualized counseling are key to help patients preserve their fertility whenever possible before cancer treatment.
Endometrial cancer starts when cells in the inner lining of the uterus grow abnormally and can spread. Some key risk factors include excess estrogen exposure without progesterone opposition, obesity, late menopause, and family history. Common symptoms are abnormal vaginal bleeding or discharge. Diagnosis involves endometrial biopsy and other imaging tests. Treatment options include surgery to remove the uterus and surrounding tissue, radiation therapy, chemotherapy, hormone therapy, and targeted therapies. The cancer is staged based on how much it has spread in the body.
Fertility preservation in Cancer patientsArunSharma10
The need for fertility preservation
Chemotherapeutic drugs according to gonadotoxicity level
Fertility preservation: subject of continuous review by experts
Non-oncological conditions requiring fertility preservation
Delayed childbearing
AVAILABLE PROCEDURES FOR FP
Embryo and oocyte cryopreservation
fertililty sparing surgeries in gynecological cancersSreelasya Kakarla
- Fertility preservation is important for cancer patients of childbearing age to maintain their quality of life. Advances in cancer treatment like chemotherapy and radiation can impact fertility.
- For early stage cervical cancers like stage 1A1, 1A2, and 1B1, fertility sparing surgeries like conization or radical trachelectomy combined with lymph node dissection may be options to preserve fertility while treating the cancer.
- For early stage ovarian and endometrial cancers, fertility sparing surgeries like cystectomy or tumor resection with lymph node sampling can be considered to treat the cancer and spare fertility in select cases.
Menopause for the mrcog and beyond, second editionnermine amin
This document discusses definitions related to menopause and controversies surrounding hormone replacement therapy (HRT). It defines key terms like menopause, perimenopause, and postmenopause. It also outlines the stages of reproductive aging. Two large studies, the Women's Health Initiative (WHI) and Million Women Study, found risks of HRT that led to controversies. The WHI was a randomized clinical trial of over 68,000 women aged 50-79 investigating HRT and other interventions. It found HRT increased risks of breast cancer, stroke, and heart disease and was stopped early.
Deborah Collyar, President, Patient Advocates In Research, discusses what new research is telling us about DCIS, both here and abroad. What is low risk DCIS? Is it okay to monitor your DCIS? Is Endocrine Therapy absolutely necessary? What does the future look like? Deborah addresses this and so much more.
This research article examines the incidence and consequences of unexpected malignancy or lesions following power morcellation during minimally invasive surgery for presumed uterine fibroids. The study analyzed 3013 laparoscopic myomectomies performed over 10 years. It found an unexpected diagnosis rate of 0.23%, including sarcomas in 0.10% of cases. One of the four patients who underwent staging surgery following diagnosis was found to have peritoneal dissemination and died from the disease. The risks of disseminating unexpected malignancy and poor long term outcomes are concerning. The article discusses the debate around continuing versus restricting power morcellation and the need for improved pre-operative diagnostic tools and patient counseling on alternative treatment options and risks.
Diagnosis of endometriosis in the 21 st centuryArunSharma10
Diagnosis of endometriosis is a challenge
Unmet needs in diagnosis of endometriosis
Non-invasive diagnosis of endometriosis
Urinary biomarkers
Peripheral biomarkers
Genetic predisposition in endometriosis
Genetic tests in endometriosis
Tissue biomarkers
miRNAs in the diagnosis of endometriosis
Endometriosis diagnosis
Introduction: Ovarian reserve is defi ned as the existent quantitative and qualitative follicular supply found in the ovaries which may turn into mature follicles and assigns a woman’s reproductive potential. The commonly appointed tests of ovarian reserve can be divided into static markers (FSH, estradiol, inhibin-B and [AMH] Anti-Mullerian Hormone), dynamic markers (clomiphene citrate, gonadotrophins and Gonadotrophin Releasing Hormone [GnRh] analogue stimulation tests) and ultrasonographic markers (Antral Follicle Count [AFC],
ovarian volume and ovarian blood fl ow). Leiomyomas are the most common genital tract tumors of benign nature and the most frequent benign uterine disorder in women of reproductive period.
This document provides information about breast cancer trends and facts. It discusses:
- Breast cancer is the most common cancer in women and the second leading cause of cancer death in women. Incidence rates have been rising but mortality rates have been declining since 1989 due to earlier detection and improved treatments.
- Risk factors include age, family history, dense breasts, obesity, hormone therapy use, alcohol consumption and lack of physical activity. Molecular subtypes have different survival rates and prevalence among racial groups.
- Screening guidelines and risk assessment tools can help determine screening recommendations for average and high-risk women. Lifestyle changes like diet, exercise and weight management may lower risk. Targeted therapies have improved survival for HER2
This review article discusses when hysterectomy should replace myomectomy for treating benign uterine conditions like fibroids. It summarizes various treatment options for fibroids including myomectomy, hysterectomy, uterine artery embolization, magnetic resonance-guided focused ultrasound, and hormonal therapies. The costs of fibroids and different surgical approaches like hysteroscopic, laparoscopic, and robotic myomectomy are also considered. Key factors in deciding between myomectomy and hysterectomy include the patient's desire to preserve fertility, the size and location of fibroids, risk of recurrence, and potential for complications.
This document discusses fertility preservation options for adolescents and young adults undergoing cancer treatment. It provides an overview of the risks cancer treatments pose to fertility for both males and females. For males, sperm banking and testicular tissue freezing are discussed as options. For females, embryo banking, oocyte cryopreservation, and ovarian tissue freezing are covered, though many methods are still considered experimental. The challenges of discussing fertility with young patients and barriers to accessing fertility preservation are also summarized.
Fertility preservation in cancer patientsRohit Kabre
This document discusses fertility preservation options for cancer patients undergoing treatment. It outlines how chemotherapy and radiation can damage the ovaries and testes, potentially causing infertility. It reviews fertility preservation methods like embryo, oocyte, and sperm cryopreservation, which are established options. Experimental options discussed include ovarian tissue and testicular tissue cryopreservation. The document also summarizes ASCO guidelines recommending discussing fertility preservation with all eligible patients and referring them to specialists.
This document summarizes several breast cancer risk assessment models. It discusses two main types of risk assessment: the chances of developing breast cancer over time, and the chances of carrying a mutation in a high-risk gene like BRCA1/2. Several models are described that assess these risks, including the Gail model, Claus model, BRCAPRO, and Cuzick-Tyrer models. Each model incorporates different sets of risk factors and has varying levels of validation and ability to predict cancer risk. The document advocates that improved models integrating more genetic and lifestyle risk factors could achieve more accurate individualized risk prediction.
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
- Metastatic breast cancer poses significant challenges as it is incurable and can recur even after early-stage treatment, with over 500,000 deaths worldwide annually. Living with metastatic disease differs profoundly from early-stage experiences.
- Two surveys of over 1,000 metastatic breast cancer patients across countries found high levels of fear, confusion and depression upon diagnosis. While most received family support, many felt stigma and isolation. Information seeking helped patients cope.
- More research funding and clinical trials inclusive of quality of life are needed. Counting metastatic cases is important to assess needs and allocate resources for supportive care and treatments that meaningfully extend survival and quality of life for these patients. Guidelines can help patients navigate a still deadly disease.
- Endometrial hyperplasia is an abnormal proliferation of the endometrium that can develop due to unopposed estrogen stimulation. It is classified based on complexity of the glands and presence of atypia.
- Risk factors include obesity, estrogen therapy without progesterone, tamoxifen use, and hereditary conditions. Symptoms include abnormal vaginal bleeding. Diagnosis involves ultrasound and endometrial biopsy.
- Treatment options include progestin therapy, which can cause regression in many cases. Hysterectomy is recommended for atypical or complex hyperplasia that is resistant to medical management due to increased risk of progression to cancer. Close monitoring is required after treatment.
We Are Social's comprehensive new Digital in 2016 report presents internet, social media, and mobile usage statistics and trends from all over the world. It contains more than 500 infographics, including global data snapshots, regional overviews, and in-depth profiles of the digital landscapes in 30 of the world's key economies. For a more insightful analysis of the numbers contained in this report, please visit http://bit.ly/DSM2016ES.
Presentation at Chittaranjan Seva Sadan, Kolkata where Dr Dasgupta was invited as faculty in the CME organized by Medical Education and research Committee, Bengal Obstetrics and Gynaecological Society
Fallopian tube radiology - Dr. Sumit SharmaSumit Sharma
The document discusses the fallopian tubes (also known as uterine tubes), including their anatomy, development, histology, diseases, and radiological evaluation. Some key points:
- The fallopian tubes connect the ovaries to the uterus and allow the passage of eggs. They have distinct segments including fimbriae, infundibulum, ampulla, and isthmus.
- A hysterosalpingogram is commonly used to evaluate the uterus and fallopian tubes for infertility or recurrent miscarriage. It can identify conditions like tubal blockage, polyps, or hydrosalpinx.
- Diseases of the fallopian tubes include congenital abnormalities, infections which
Endometrial carcinoma is the most common gynecologic malignancy, predominantly affecting postmenopausal women. It is twice as common as ovarian cancer and three times more common than cervical cancer. The main risk factors are obesity, a high intake of animal fats, and use of unopposed estrogen therapy. Abnormal vaginal bleeding is the most common symptom and prompts diagnosis, usually at an early stage. Screening is not routinely recommended but may be considered for high risk groups like tamoxifen users. Pathologic examination determines histologic type and grade, which predict clinical behavior.
Endometrial cancer is the most common gynecologic cancer. It has a lifetime risk of 2.4% in white women. Risk factors include obesity, late menopause, diabetes, and unopposed estrogen exposure. Diagnosis is usually made with endometrial biopsy. Treatment involves hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection. Adjuvant radiation and/or chemotherapy may be used in high risk cases. With early stage diagnosis, endometrial cancer has a good prognosis.
a nice presentation about the Ovarian Cancer its include an introduction with brief notes about the epidemiology and risk factors then shift to pathology and pathogenesis and diagnosis with signs , symptoms and lab tests with imaging modules , screening , management
The uterus is a pear-shaped organ divided into the fundus, body, and cervix. Lymph drainage from the fundus goes to para-aortic nodes at L1, while the body and cervix drain to internal and external iliac nodes. Endometrial cancer is the most common gynecologic malignancy in the US, with risk factors including age, estrogen exposure, genetics, and medical history. Treatment depends on staging and includes surgery, radiation, chemotherapy, and hormonal therapy.
This document discusses endometrial cancer. It is the most common gynecologic malignancy in the US, with a 3% incidence rate that is increasing. Most cases are diagnosed early as abnormal vaginal bleeding prompts medical evaluation. Obesity, unopposed estrogen exposure, and genetics increase risk. Treatment depends on cancer stage, grade, and subtype, but commonly involves hysterectomy with or without additional therapies like radiation or chemotherapy. Outcomes are best for early stage, low grade endometrioid adenocarcinoma.
Tara PowerPoint An In Depth Look At Breast CancersTara Sorg
This document provides an in-depth overview of breast cancer, including:
1) Classifying breast cancers based on microscopic evidence, proteins, and other factors.
2) How genes and proteins can affect breast cancer behavior.
3) Identifying and explaining common breast cancer types like invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), inflammatory breast cancer, and triple negative breast cancer.
4) Discussing diagnostic imaging, grading, prognosis, and treatment for each type.
This document provides an overview of breast anatomy, epidemiology, risk factors, and pathology of breast cancer. It discusses the anatomy of the breast and its blood supply. It notes that breast cancer is the most common cancer in women worldwide and outlines risk factors such as age, family history, genetics, reproductive history, and lifestyle factors. The document also describes different histological types of breast cancer including in situ and invasive ductal and lobular carcinomas. It discusses molecular subtypes defined by gene expression and prognosis.
This document summarizes the key findings of a survey conducted by the Working Mother Research Institute on women's knowledge and attitudes around breast cancer screening and breast health. Some of the main findings include:
- 9 out of 10 women consider mammograms an important part of health management and 80% have had at least one mammogram, with 70% getting screened annually.
- However, many women lack knowledge about breast density and its health implications, and options for screening technologies. Nearly half did not know if they had dense breasts.
- Of women who had a mammogram, 5 out of 10 were called back for additional testing, with most finding nothing suspicious but some receiving cancer diagnoses.
- The document reviews
Breast cancer is the most common cancer in women. Rates are higher in Black women than White women due to disparities in screening and treatment. Genetic and lifestyle factors affect risk, and regular screening is recommended starting at age 40. However, some groups face barriers to screening like lack of access to care, knowledge, and cultural beliefs. Researchers are working to better understand risk factors and improve prevention and individualized treatment through studies on genetics, screening methods, and high-risk populations.
Report Back from ASCO on Metastatic Breast Cancerbkling
Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, shares her experiences from the American Society of Clinical Oncology's June 2017 Conference. She also updates us on the latest research from the conference as it relates to metastatic breast cancer.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
About this webinar:
Breast radiologist Dr. Paula Gordon will discuss the optimal strategy for achieving early detection of breast cancer. She will also describe the flawed process used in making Canadian breast screening guidelines, impacting millions of women. Patient advocate Jennie Dale from Dense Breasts Canada will look at the inequities in breast cancer screening and surveillance practices in Canada. She will also explore ways to advocate for better screening and surveillance.
About the presenters:
Dr. Paula Gordon is a Clinical Professor in the Department of Radiology at the University of British Columbia, and has been practicing for over 35 years. She is Founding Medical Director of the Sadie Diamond Breast Program at BC Women’s Hospital, and a founding member of the Canadian Society of Breast Imaging. She’s given hundreds of lectures at meetings around the globe. She received a Queen Elizabeth Diamond Jubilee Medal, and was invested in the Order of British Columbia. She was named one of Canada’s 100 Most Powerful Women by the Women’s Executive Network.
Jennie Dale is the Co-founder and Executive Director of Dense Breasts Canada (DBC). She was diagnosed with breast cancer in October 2014. Inspired by the successful advocacy and education efforts of similar American organizations, Jennie co-founded DBC with Michelle Di Tomaso in 2016. They teamed up with breast cancer survivors, dedicated individuals, and health care professionals nationwide to raise awareness of the risks of dense breasts and advocate for patient notification of breast density and access to supplemental screening. She is fighting for necessary revisions to the current Canadian Task Force breast cancer screening guidelines, which put women's lives at risk. In 2021, Jennie was named a top 5 finalist in Charity Village's awards in the category of Most Outstanding Impact by a Volunteer.
Cervical cancer is one of the most common cancers in women worldwide. This case-control study assessed risk factors for cervical cancer in 75 women diagnosed with cervical cancer and 75 age-matched controls in India. The study found significant associations between cervical cancer and factors such as lower education, rural residence, use of old cloth sanitary napkins, early age at marriage, husband having multiple partners, lack of washing after intercourse, and poor access to healthcare services. Daily bathing and bathing during menstruation were found to be preventive. Logistic regression showed that lack of healthcare utilization and presence of sexually transmitted infections were significantly associated with cervical cancer. The study aims to identify cervical cancer risk factors to enable early screening and diagnosis.
A study of lifestyle of women in breast cancer in kailash cancer hospital and...Samit Shah
This document summarizes a study conducted on women with breast cancer at the Kailash Cancer Hospital and Research Center in Goraj, India. The study was conducted by Archana Bhatt and Anita Rakhe to fulfill their master's degree requirements. It examines the situation of women diagnosed with breast cancer, including their physical and mental health, family support, and treatment experiences. Key findings included that most participants were illiterate and complained of tumors in their breasts. The document provides context on breast cancer risks, symptoms, screening and theories of progression. It aims to understand patient experiences and provide recommendations to support women's healthy and happy lives.
This document discusses prevention of breast and cervical cancer in women. It covers leading causes of death for women, risk factors, screening methods, symptoms, and preventive measures. The key points are:
1) Heart disease, cancer, and stroke are the top three leading causes of death for women. Cancer screening and treatments have improved survival rates to 66% for people diagnosed between 1966-2002.
2) Risk factors for cancer include age, family history, lifestyle factors like smoking, and genetic conditions. Screening methods include self-exams, clinical exams, mammography, and HPV testing to detect cancers early.
3) Preventive measures include vaccinations, safe sexual practices, smoking cessation, healthy
This document provides information about breast cancer including epidemiology, risk factors, detection, diagnosis, and management. Some key points include:
- Breast cancer is the most common cancer in females in the UAE and incidence is increasing worldwide.
- Risk factors include age, family history, reproductive history, breast density, genetic factors, lifestyle factors like obesity and alcohol.
- Detection methods include breast self-exams, clinical exams, mammography and MRI.
- Diagnosis involves biopsy after an abnormal finding. Staging evaluates tumor size, node involvement and metastasis.
- Treatment depends on stage and includes surgery, radiation, chemotherapy, hormone therapy and targeted therapy.
Knowledge Discovery from Breast Cancer Databaseiosrjce
In this paper, we study various factors leading to breast cancer and also a few symptoms that act as
biomarkers for the occurrence of breast cancer in women. Totally 18 factors are taken for study. Statistical
techniques are used to analyze the influence of various factors towards the disease and test for significance of
factors is also done. Besides association rule mining is attempted to generate possible factors that may lead to
breast cancer. An attempt to classify the given dataset using information gain techniques and CHAID
techniques was done. Clustering was also done to predict the occurrence of breast cancer. The results show
that there is more possibility of developing breast cancer among married working women who have breast fed less than 2.5 years in total.
This document discusses breast cancer, including risk factors, screening methods, symptoms, and management. It notes that breast cancer is the most common cancer among Indian women, affecting one in 21. Risk factors include increasing age, family history, genetic mutations, early menarche, late menopause, and increased breast density. Screening methods like breast self-examination, clinical examination, and mammography can aid in early detection. Management may involve surgery, chemotherapy, radiotherapy, or hormonal therapy depending on the cancer characteristics. Maintaining a healthy lifestyle and being breast aware can help reduce risks.
Cancer and screening - A presentation by Cancer RoseCancer Rose
Cancer Rose is a French non-profit organization of health professionals.
Independent French medical doctors and a doctor in toxicology, have created the site www.cancer-rose.fr to inform you of the most recent and relevant data on breast cancer mass screening.
By decoding and popularizing the most recent research findings published in the most important international medical journals, analyzing the controversy and providing a social and feminine analysis, our objective is to inform women concerned by breast cancer mass screening in order to help them making their choice and to provide independent information resources to interested physicians.
Cancer Rose has no sponsorships, honoraria, monetary support or conflict of interest from any commercial sources.
breast cancer
cancer
epidemiology
community medicine
awareness of breast cancer
سرطان الثدي
وبائيات سرطان الثدي
epidemiology of breast cancer
prevention of breast cancer
risk factors of breast cancer
epidemiology of breast cancer in iraq
sign and symptoms of breast cancer
location of breast cancer
Breast cancer is a malignant tumor that develops in breast tissue. It is the leading cause of cancer death for women between ages 40-55 worldwide. While rare, men can also develop breast cancer. Annual mammograms are recommended starting at age 40 to detect breast cancer early. Some risk factors include family history, genetic factors, lifestyle factors like alcohol consumption and physical inactivity. Common signs include a new lump in the breast or skin changes. Monthly self-exams and yearly clinical exams can help detect changes early. Treatment options depend on cancer stage and type but may include surgery, chemotherapy, radiation, and hormone therapy. With early detection and treatment, breast cancer has a high cure rate.
Breast cancer screening-2021 chan hio tongjim kuok
This document discusses breast cancer screening and provides guidance on screening strategies based on risk level. It covers:
1) Screening modalities like mammography, ultrasound, MRI and their limitations. Mammography is the primary screening tool for average risk women aged 50-74.
2) Risk assessment factors like family history, genetic mutations, breast density, reproductive history which determine screening frequency and additional tests. Women at high risk start screening earlier and more frequently.
3) Two case studies where mammography limitations are demonstrated. Early detection through clinical exams and additional tests led to cancer diagnosis in both cases. Regular screening tailored to risk level can improve early detection.
Breast Cancer Essay examples
Essay on Breast Cancer Treatment
Essay on Breast Cancer
Essay On Breast Cancer
Essay on Breast Cancer
Breast Cancer Essay
Essay on Breast Cancer
Essay on Breast Cancer Awareness
Essay on Breast Cancer
My talk to National Breast Cancer Coalition Project LEAD® workshop 2014Gary Schwitzer
Delivered in Washington, DC, on November 16, 2014. These slides also became the basis for a talk I gave via Skype to Doug Starr's class in the graduate Program in Science and Medical Journalism at Boston University on November 19.
Similar to Malignancy of the endometrium, ov, ft (20)
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
9. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
DIAGNOSIS
• Histologic examinaRon of the endometrium
• Office Endometrial Biopsy
– Novak’s curet
– Pipelle- useful if the endometrial thickness of >6mm
– 1st line in the diagnosis of endometrial cancer
– Endometrial sample is obtained in the clinic with no
anesthesia
– Advisable only for postmenopausal women with
thickened endometrium (not for pre-menopausal
women)
49. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Cancer AnRgen (Ca) 125
• Generally used in epithelial ovarian cancer
• Used in advanced stage endometrial cancer to
detect extrauterine involvement and as post-
operaRve monitoring
• Not useful in early stage disease
• Non-specific to endometrial cancer
50. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
SURGERY
• primary treatment modality
• Surgicopathologic staging (using the 2009
FIGO Staging system)
• ExcepRons:
– PaRents with poor surgical risk due to unstable
medical condiRons
– Young cancer paRents desirous of future ferRlity
– Will use the 1971 FIGO Clinical Staging System of
Endometrial cancer
52. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Surgery
• Surgical staging
(1) tumor spread within the uterus
(2) degree of penetraRon into the myometrium
(3) extrauterine spread to retroperitoneal
nodes, adnexa, and/or the peritoneal cavity
56. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
RadiaRon
• RadiaRon alone: Inferior than surgery
– Stage 1 surgery alone: 87% 5 yr survival versus
67% for radiaRon alone
– Not recommended for paRents desirous of
pregnancy (radiaRon will kill the ovaries)
• As adjuvant therapy: given post-operaRve
treatment if with poor prognosRc factors
– Increases survival of paRents with advanced
endometrial cancer
62. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Medical/ ConservaRve treatment
ConservaRve treatment is only offered to paRents who
have:
• Well differenRated tumor (endometrioid type)
• No myometrial invasion (as evaluated by MRI)
• No cervical involvement
• No extrauterine involvement:
– No adnexal involvement
– No parametrial involvement
– No vaginal involvement
– No suspicious retroperitoneal nodes or no evidence of
lymph node metastasis
– NegaRve PFC
• No LVSI (lymphovasular space invasion)
• No contraindicaRons for medical management
SGOP 2015 CPG
65. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Medical/ ConservaRve treatment
Monitoring:
• repeat dilataRon and curefage auer 3 months of
therapy
• No response auer 3 months of therapy =
treatment failure
• maintenance treatment with oral contracepRve
pills (OCPs), cyclic progesRns, depot
medroxyprogesterone acetate (DMPA), or LNG-
IUS unRl pregnancy is desired
• If pregnancy is desired, afempts should be made
auer 3 months from reversion of the cancer.
73. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
DIAGNOSIS
• Ultrasound remains to be the most helpful imaging
examinaRon for ovarian cancer diagnosis with the highest
sensiRvity
• CA 125 and HE4 (more specific tumor marker for ovarian
cancer)
*However, ROUTINE screening for average-risk women using
TVUTS, CA 125 and pelvic exam is not recommended
75. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Risk Factors
• No definite cause
Factors that increase risk:
• Nulliparity
• Menstrual irregulariRes
• Hx of breast or endometrial cancer
Factors that could be protecRve:
• Pregnancy
• Oral contracepRves
77. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Contrast of Surgical Findings
Benign Malignant
Surface papillae Rare Very common
Intracytic papillae Uncommon Very common
Solid areas Rare Very common
Bilaterality Rare Common
Adhesions Uncommon Common
Ascites (>100 ml) Rare Common
Necrosis Rare Common
Peritoneal
implants
Rare Common
Capsule intact Common Infrequent
Totally cystic Common Rare
78. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO 1988 FIGO 2014
FIGO Guidelines Commifee:
Revise the staging system to improve uRlity
and reproducibility
Ovarian, Fallopian tube and primary
peritoneal cancer: same staging system
because of common histology: Serous type
79. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 1
NEW STAGING OLD STAGING
I Tumor confined to ovaries or fallopian
tube(s)
Tumor limited to the ovaries (one
or both)
IA Tumor limited to one ovary (capsule
intact) or fallopian tube
No tumor on ovarian or fallopian tube
surface
No malignant cells in the ascites or
peritoneal washings
Tumor limited to one ovary;
capsule intact
No tumor on ovarian surface
No malignant cells in ascites or
peritoneal washings
IB Tumor limited to both ovaries
(capsules intact) or fallopian tubes
No tumor on ovarian or fallopian tube
surface
No malignant cells in the ascites or
peritoneal washings
Tumor limited to both ovaries;
capsule intact
No tumor on ovarian surface
No malignant cells in ascites or
peritoneal washings
80. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 1
NEW STAGING OLD STAGING
I
Tumor confined to ovaries or fallopian
tube(s)
Tumor limited to the ovaries (one
or both)
IC
IC1
IC2
IC3
Tumor limited to one or both ovaries or
fallopian tubes with any of the
following:
Surgical spill intraoperatively
Capsule ruptured before surgery or
tumor on ovarian or fallopian tube
surface
Malignant cells in the ascites or
peritoneal washings
Tumor limited to one or both
ovaries with any of the following:
Capsule ruptured, tumor on
ovarian surface, malignant cells in
ascites or peritoneal washings
81. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 2
NEW STAGING OLD STAGING
II Tumor involves one or both ovaries or
fallopian tubes with pelvic extension
(below pelvic brim) or primary
peritoneal cancer
Tumor involves one or both
ovaries with pelvic extension
IIA Extension and/or implants on the
uterus and/or fallopian tubes and/or
ovaries
Extension and/or implants on
uterus and/or tube(s); no
malignant cells in ascites or
peritoneal washings
IIB Extension to other pelvic
intraperitoneal tissues
Extension to other pelvic tissues
No malignant cells in ascites or
peritoneal washings
IIC
Pelvic extension (IIa or IIb) with
malignant cells In ascites or
peritoneal washings
82. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 3
NEW STAGING OLD STAGING
III Tumor involves one or both
ovaries, fallopian tubes, or
primary peritoneal cancer, with
cytologically or histologically
confirmed spread to the
peritoneum outside the pelvis
and/or metastasis to the
retroperitoneal lymph nodes
Tumor involves one or
both ovaries with
microscopically
confirmed peritoneal
metastasis outside the
pelvis and/or regional
lymph node metastasis
83. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 3
NEW STAGING OLD STAGING
IIIA IIIA1
PosiRve retroperitoneal lymph
nodes only (cytologically or
histologically proven)
(i) Metastasis < 10 mm in greatest
dimension
(ii) Metastasis >10 mm in greatest
dimension
IIIA2
Microscopic extrapelvic (above the
pelvic brim) peritoneal involvement
with or without posiRve
retroperitoneal lymph nodes
Microscopic peritoneal
metastasis beyond pelvis
84. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 3
NEW STAGING OLD STAGING
IIIB Macroscopic peritoneal
metastasis beyond the pelvis up
to 2 cm in greatest dimension,
with or without metastasis to
the retroperitoneal lymph nodes
Macroscopic peritoneal
metastasis beyond the
pelvis, 2 cm or less in
greatest dimension
85. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 3
NEW STAGING OLD STAGING
IIIC Macroscopic peritoneal
metastasis beyond the pelvis
more than 2 cm in greatest
dimension, with or without
metastasis to the retro-
peritoneal lymph nodes
(includes extension of tumor to
capsule of liver and spleen
without parenchymal
involvement of either organ)
Peritoneal metastasis
beyond pelvis, more
than 2 cm in greatest
dimension and/or
regional lymph node
metastasis
86. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
FIGO STAGE 4
NEW STAGING OLD STAGING
IV
Distant metastasis excluding
peritoneal metastases
IVA: Pleural effusion with posiRve
cytology
IVB: Parenchymal metastases and
metastases to extra-abdominal
organs (including inguinal lymph
nodes and lymph nodes outside
the abdominal cavity)
Growth involving one or
both ovaries with distant
metastases. If pleural
effusion is present, there
must be posiRve cytology
to allot a case to Stage IV.
Parenchymal liver
metastasis equals Stage IV
88. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Borderline tumor/ Low Malignant
PotenRal
• 10 to 15% of epithelial ovarian cancers
• Most common: early stage
• Rarely metastasize in lymph nodes
• Nuclear atypia, straRficaRon of the epithelium,
formaRon of microscopic papillary projecRons,
cellular pleomorphism, and mitoRc acRvity
• ABSENCE of stromal invasion
• Recurrence is possible (usually late)
89. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Pathology: Serous CA
• >50% of ovarian cancer are serous histology
• Predominantly cysRc with thin fluid within
with papillary excresences/ mural nodule
• Resembles the fallopian tube epithelium
• Pathognomonic: PSAMMOMA BODIES
• CA-125: most useful tumor marker
96. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
This can be cystic with smooth
surface and variable amounts of
intracystic soft or solid masses or
papillae. This can sometimes
have necrosis and hemorrhage.
There is irregular, infiltrative proliferation of
glandular type epithelium resembling
proliferative type endometrium with
cytologically malignant nuclear features.
Pathology: Endometrioid
97. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Pathology: Mucinous
• 5 to 10 percent of true epithelial ovarian cancers
• MulRloculated, mulRcysRc mass with thick
material within
• Resembles mucin-secreRng adenocarcinomas of
intesRnal or endocervical origin
• Associated with appendiceal tumor and
pseudomyxoma peritonei
• CA-19-9 (tumor marker for mucin-producing cells
like appendix, pancreas, intesRne)
104. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
• Surgery
– (USO) with frozen secRon (FS) is permifed for
young paRents with stage I
– Infracolic omentectomy or infragastric
omentectomy
– Random peritoneal biopsies (undersurface of
the right hemidiaphragm, bladder reflecRon,
cul-de-sac, right and leu paracolic recesses
and pelvic sidewalls)
– Pelvic and paraaorRc lymph node sampling
– Appendectomy for mucinous tumors
107. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Germ Cell tumors
• most common ovarian malignancies
diagnosed during childhood and adolescence
• Symptoms are similar to the epithelial
counterpart
• Mass does not grow as big as the epithelial
tumors
109. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Dysgerminoma
• Most common malignant ovarian germ cell tumor
• Most common ovarian malignancy detected during
pregnancy
• the only germ cell malignancy with a significant rate of
bilateral ovarian involvement (15-20%)
• In general: Solid, cream-colored tumor
• large, rounded, polyhedral clear cells that are rich in
cytoplasmic glycogen with lymphocyte infiltraRon
• Lactate Dehydrogenase (LDH)- an impt. tumor marker
• 5%- (+) HCG
114. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
IMMATURE TERATOMA
• 3rd most common malignant germ cell tumor
• Gross: solid w/ cysRc spaces
• Micro: immature Rssue derived from 3 germ
layers
• usually from endodermal, e.g.
neuroepithelium
• Tumor marker: AFP
115. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
This typically has a smooth surface
and is cystic. Cut section
demonstrates greasy yellow
sebaceous material and hair. Often
there is a thickening of the cyst wall
(Rokitansky's protuberance) from
which hair and sometimes teeth and
bone arise.
This cystic structure is lined
predominantly by skin and cutaneous
adnexal structures, usually with abundant
sebaceous and sweat glands. Hair is
almost always present. Other
components include cartilage, bone,
bronchial or gastrointestinal epithelium
and mature
glial tissue. If only skin and adnexal
structures are present it can be termed
dermoid cyst.
Sebace
ous
land
skin
117. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Immature GlandsImmature Neural
Tissue
Immature Cartilage
The diagnosis of this tumor requires the presence of immature elements
derived from any of the three germ layers: skin elements, mature neural
tissue, connective tissue, cartilage, bone, gastrointestinal or bronchial
epithelium.
IMMATURE TERATOMA
128. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Granulosa-cell tumor
• Juvenile Granulosa cell tumor
– children and young adults, and half are diagnosed
before puberty. The mean age at diagnosis is 13
years
– isosexual peripheral precocious puberty
– More aggressive
133. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
This tumor typically has rounded,
firm, white masses that may be
bosselated, yellow or white on cut
section. Fleshy, gelatinous or spongy
areas are common.
Presence of mucin-laden, signet-ring cells strewn
individually and in small clusters within a hypercellular
ovarian stroma (occasionally with storiform pattern).
The cytoplasm occasionally is granular and
eosinophilic rather than pale and vacuolated
(sometimes has bull's-eye appearance, containing
large vacuole with central eosinophilic body).
Krukenberg tumor
136. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
The oviducts, or fallopian tubes, vary from 8 - 14 cm in
length and are covered by peritoneum. It is divided into the
following potions: interstitium (a), isthmus (b), ampulla (c),
and infundibulum (d).
d
c
b
aa
b
c
d
Nomal Fallopian Tube
138. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
This is composed of fine branching papillae (Arrow)
covered by one or more layers of epithelium with
enlarged pleomorphic hyperchromatic nuclei (inset).
There is increased and abnormal mitoses. In poorly
differentiated areas, the tumor may grow in solid
sheets of cells with small or large foci of necrosis.
Invasive Adenocarcinoma Of Fallopian Tube
139. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Pathology
• The majority (88%) of PFTCs were adenocarcinomas;
– Serous 44%
– Endometrioid 19%.
– Mixed 3.9 – 16.7%
– UndifferenRated 7.8 – 11.3%
– Mucinous 3 – 7.6%
• Tumor Grade
– Grade I 15 – 20%
– Grade II 20 – 30%
– Grade III 50 – 65%
• Laterality
– Unilateral 89%
– Bilateral 11%
• Stage at diagnosis was fairly evenly distributed
– localized (36%)
– regional (30%)
– distant (32%) Stewart et al,
2007
140. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
Clinical Features
Clinical Features Percentage
Vaginal bleeding or spotting 50%–60%
Abdominal pain, colicky or dull 30%–49%
Abdominal or pelvic mass 60% (range, 12%–84%)
Ascites 15%
Rare presentations (acute abdomen, palpable
inguinal node, umbilical-bone cerebral
metastases, cerebellar degeneration,
asymptomatic)
[38–41]
Postmenopausal bleeding or spotting with
negative Pap smear
Pectasides et al, 2009
141. 24/03/2017 #DLSHSI_GYNEONCO2017 @doc_magno
LATZKO’S TRIAD
A syndrome which consists of:
1) profuse watery or honey-colored vaginal
discharge,
2) a pelvic mass, and
3) colicky pelvic pain that essenRally goes
away upon sudden disappearance of the
mass
Although this triad is rarely found in pracRce,
it’s a classic diagnosRc syndrome for
fallopian tube disease.
Sotto & Manalo, 1994